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SUMMARY
Cryptosporidiosis is a neglected disease without
a wholly effective drug. We present a study dem-
onstrating nitrogen-containing bisphosphonates
(N-BPs) to be capable of inhibiting Cryptosporidium
parvum at lowmicromolar concentrations in infected
MDCK cells. Predictably, the mechanism of action is
based on inhibition of biosynthesis of isoprenoids
but the target enzyme is unexpectedly a distinctive
C. parvum enzyme dubbed nonspecific polyprenyl
pyrophosphate synthase (CpNPPPS). This enzyme
produces various isoprenoid products larger than
FPP and is inhibited by N-BPs at subnanomolar
concentrations. It is part of an isoprenoid pathway
in Cryptosporidium distinctly different from other
organisms. The proposed mechanism of action is
corroborated by crystal structures of the enzyme
with risedronate and zoledronate bound showing
how this enzyme’s unique chain length determinant
region enables it to accommodate larger substrates
and products. These results, combined with existing
data on their clinical use, demonstrate that N-BPs are
very promising anticryptosporidial drug candidates.
INTRODUCTION
Given their significant impact on global health, protozoan
diseases do not benefit from a proportionate share of research
support and are therefore often classified as neglected diseases.
An example is cryptosporidiosis (Savioli et al., 2006), a potentially
severe enteric disease primarily affecting pregnant women,
immunocompromised individuals, and children. Millions of Asian
and African children under 5 years of age suffer repeated infec-
tion and consequently intellectual stunting (Berkman et al., 2002;
Ricci et al., 2006). In addition,Cryptosporidium parvum is amajor
cause of livestock infection and is classified as a class Bbioterror
agent.
Themost commonprescriptions for cryptosporidiosis are nita-
zoxanide and the antibiotic paromomycin, with the former
approved for otherwise healthy adults and children older than
1 year of age (Smith and Corcoran, 2004). Neither is targeted
therapy with known mechanism of action. In general, efforts to
identify and validate Cryptosporidium drug targets are compli-
cated by the parasite’s resistance to genetic manipulation and
long-term cultivation. Even with the establishment of a promising
drug target, the traditional drug-discovery cycle that follows—
including discovery and optimization of novel inhibitory
compounds, ADME/toxicity assessment, and finally animal and
clinical studies—is too long, expensive, and prone to failure for
an infectious disease that requires a therapeutic solution sooner
rather than later.
In lieu of developing novel drugs, revisiting known chemical
space and investigating the efficacy of compound classes first
developed for diseases other than cryptosporidiosis might prove
to be highly efficient, particularly if such compounds have known
favorable pharmacokinetic properties or, better still, are already
in clinical use. For example, in vitro studies have shown nitrogen-
containing bisphosphonates (N-BP), many of which are clinically
approved for treatment of bone metabolism disorders, to be
effective in killing bacterial pathogens such as Staphylococcus
aureus (Liu et al., 2008) as well as other protozoan parasites
including Plasmodium, Toxoplasma, Leishmania, and Trypan-
soma (Sanz-Rodriguez et al., 2007). Their utility on cryptosporid-
iosis has not been studied to the same extent; however, previous
preliminary work has indicated that one member of the N-BP
family is effective against experimental cryptosporidiosis in
a mouse xenograft model (Moreno et al., 2001).
Clinically, N-BPs are widely used to treat bone metabolism
disorders, such as osteoporosis (Delmas, 2002). In these treat-
ments, N-BPs inhibit the isoprenoid pathway by binding to their
molecular target, namely farnesyl pyrophosphate synthase
(FPPS) (van Beek et al., 1999; Bergstrom et al., 2000; Fisher
et al., 2000; Rogers et al., 2000; Dunford et al., 2001). Similarly,
the isoprenoid pathway has been considered a drug target for
protozoan diseases, including malaria, Chagas’ disease, toxo-
plasmosis, and leishmaniasis (Ling et al., 2005; Martin et al.,
2001; Moreno et al., 2001). In C. parvum, the importance of
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Targeting a Uniquely Nonspecific Prenyl Synthaseisoprenoids is supported by the prediction of at least three prenyl
synthases in the genome (data not shown); however, unlike Plas-
modium and Toxoplasma parasites, which employ the MEP
pathway (Figure 1), the path leading to production of substrates
for these enzymes, including isopentenyl pyrophosphate (IPP)
and dimethylallyl pyrophosphate (DMAPP), is unclear,
because the requisite enzymes have not been found by experi-
ment or genomic analysis (Clastre et al., 2007). At this point, it
is unknown whether the Cryptosporidium genus of parasites
relies heavily on salvage or on a completely different pathway
for isoprenoids.
In our study, we chose a panel of N-BPs to quantify their effec-
tiveness in aMDCK (Madin Darby canine kidney) cellCryptospo-
ridium infection model. To investigate the mechanism of action,
the C. parvum enzyme most closely homologous to FPPS and
GGPPS was expressed and characterized by means of
biochemical assays and crystallography. Our results revealed
this enzyme to be a nonspecific polyprenyl pyrophosphate syn-
thase (NPPPS) distinguished from all previously characterized
enzymes in its unique capability to produce isoprenoid products
from C20 to longer than C45, depending on the substrate used.
Structurally, it is similar to known orthologs of polyprenyl syn-
thases including FPPS, GGPPS, and OPPS (octaprenyl pyro-
phosphate synthase) but reveals distinctive features consistent
with its nonspecific substrate preference. Notwithstanding its
novelty, CpNPPPS is efficiently inhibited by clinically relevant
concentrations of N-BPs, and is therefore a potential target for
the treatment of cryptosporidiosis.
RESULTS AND DISCUSSION
Inhibition of C. parvum Growth in MDCK Cell Culture
by N-BPs
We screened a panel of seven clinically prescribed N-BPs
against C. parvum-infected MDCK cell culture and analyzed
the effect of the drugs bymeans of immunofluorescence labeling
Figure 1. Isoprenoid Synthesis and Downstream Products
C. parvum enzyme activities (and respective products) that have been identified and characterized are in green (this work). The MVA pathway, used by most
eukaryotes for producing IPP, is absent, as is theMEP pathway employed by prokaryotes and other protozoan parasites. From genomic analysis, however, there
appear to be downstream enzymes that build on medium-length isoprenoids.
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Targeting a Uniquely Nonspecific Prenyl SynthaseTable 1. Anticryptosporidial Activity of N-BP Compounds in MDCK Cells
Compound Structure IC50 (mM) r TC50 MDCK Cells TC50 HCT-8 Cells
IBAN 3.0 0.95 >100 >500
RIS 3.5 0.94 >100 >500
ZOL 5.9 0.81 >100 >500
Pamidronate 12.1 0.61 >100 >500
NE10790 52.5 0.96 >100 >500
NE058051 >100 0.89 >100 >5001298 Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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Targeting a Uniquely Nonspecific Prenyl Synthaseof the monoclonal antibody C3C3 (see Experimental Proce-
dures). Although both MDCK and HCT-8 cells support efficient
(but not continuous) Cryptosporidium growth, MDCK cells
were chosen for our experiments because they better facilitate
digital imaging (Arrowood, 2007). As shown in Table 1, of the
seven compounds, Alendronate and NE58051 showed negli-
gible effect (IC50 > 100 mM). Pamidronate and NE10790 showed
modest anticryptosporidial activity (IC50 12.1 and 52.3 mM,
respectively) in the same order of magnitude as that of paromo-
mycin, which is the standard for anticryptosporidial candidates
(Perkins et al., 1998). Three candidates, namely risedronate
(RIS), zoledronate (ZOL), and ibandronate (IBAN), showed the
most promising activity (IC50 3 to 6 mM)—more than an order
of magnitude stronger than the inhibitory potency of paromomy-
cin and more potent than any other results cited in the literature,
based on our survey. Because all seven compounds used
showed low toxicity for MDCK up to 100 mM relative to control
cells treated with medium alone (data not shown), these results
indicate that the effective compounds entered the parasite and
inhibited their development. As an illustrative example, Figure 2
shows the significantly inhibited growth in the presence of ZOL at
100 mM versus at 1 mM.
Activity Assays: Distinctive Cryptosporidium Enzyme
Is the Target of Bisphosphonates
Bisphosphonates are known to inhibit the biosynthesis of isopre-
noids, making this a good starting point for target identification;
however, the C. parvum genome lacks the genes for both the
MVA and MEP pathways for IPP production and is further
missing isopentenyl pyrophosphate isomerase (Figure 1) for
conversion of IPP to DMAPP (Clastre et al., 2007). There is a C.
parvum enzyme with CryptoDB (Heiges et al., 2006) gene ID
cgd4_2550 (GenBank ID XP_625843), which shares 27% and
24% sequence identity, respectively, with human FPPS and
GGPPS (see multiple sequence alignment in Figure S1 available
online). We expressed the recombinant form of this protein and
measured its activity using four allylic substrates (DMAPP,
Table 1. Continued
Compound Structure IC50 (mM) r TC50 MDCK Cells TC50 HCT-8 Cells
Alendronate >100 0.28 >100 >500
IC50 represents 50% inhibitory concentration; r, linear correlation coefficient of median effect plot; TC50, 50% inhibitory (toxicity) concentration.
Figure 2. C. parvum Growth in MDCK Cells 48 h after Inoculation (PI) in the Presence of RIS
Immunofluorescence labeling of parasites utilized the Cryptosporidium-specific monoclonal antibody C3C3.
(A) Robust C. parvum growth in the presence of RIS at 1 mM (arrows).
(B) Substantial inhibition of parasite growth in the presence of RIS at 100 mM (reduced numbers of parasites, weaker antibody labeling, and smaller size of para-
sites [arrowheads]).Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved 1299
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Targeting a Uniquely Nonspecific Prenyl SynthaseGPP, FPP, and GGPP) to evaluate its substrate and product
specificities.
Product analysis by reverse-phase TLC revealed a wide range
of polyprenyl chains (Figure 3A), regardless of the substrate
used. With DMAPP as substrate, the rate of activity was low
but still sufficient to show a roughly even distribution of products
from C15 up to C45 (Table S1), with longer products occasionally
observed (up to C55). Nevertheless, the enzymewas clearly more
active with GPP, FPP, and GGPP as substrates. When GGPP
was the substrate, longer prenyl chains were also produced.
Upon addition of detergent (Tween 20), all reactions lost their
longest products. This was particularly noticeable with DMAPP
or GGPP as the substrate (Figure 3A and Table S2). In both
cases, the maximal chain length observed under these condi-
tions was C35, but the major products were C25 and C30.
Because of its versatility, we chose to call this enzyme Crypto-
sporidium parvum nonspecific polyprenyl pyrophosphate syn-
thase (CpNPPPS).
The rate of IPP incorporation using the standard assay was
barely measurable using DMAPP (Figure 3B), but we were able
to determine the kinetic parameters of CpNPPPS with other
substrates. The highest maximal velocity was obtained, in de-
scending order (Table S3), with FPP (3.1 ± 0.1 nmol/min/nmol),
GPP (1.4 ± 0.2 nmol/min/nmol), and GGPP (0.9 ± 0.1 nmol/
min/nmol). Kinetic data fit the Michaelis-Menten model and
showed the substrates to have similar KM values between 0.8
and 0.95 mM (Table S3), comparable to the values previously
determined for other prenyl synthases (Guo et al., 2007; Kava-
nagh et al., 2006a, 2006b). The KM value for IPP was found to
be 1.5 mM and also similar to other prenyl synthases (Kavanagh
et al., 2006a, 2006b). We did not observe IPP-induced substrate
inhibition with IPP concentrations up to 40 mM (data not shown).
The C. parvum enzyme CpNPPPS had an IPP incorporation rate
similar to human GGPPS, but was approximately 20-fold less
active than human FPPS (Figure 3B).
Despite being a poor substrate for CpNPPPS, DMAPP does
give a wide range of products (C15 to > C45). Mechanistically,
once this substrate begins the chain-elongation process, the
DMAPP in solution cannot compete with the bound product/
substrate. Although GGPP is a better substrate than DMAPP,
the same holds true, where products greater than C45 can be de-
tected. In the case of GPP and FPP, predominately products less
than C30 are formed and longer-chain products are virtually
undetectable. Overall, the presence of detergents leads to
a decrease in product chain length, which can be attributed to
the facilitation of product release in the presence of these large
hydrophobic molecules in the bulk solvent. In contrast to
CpNPPPS, human FPPS and GGPPS are both monofunctional
and exclusively produce FPP and GGPP, respectively (Kava-
nagh et al., 2006a, 2006b).
Enzyme Inhibition: CpNPPPS Inhibited by N-BPs
with Subnanomolar Ki Values
The potency and mode of binding for the three most potent anti-
cryptospordial compounds from our experiments, namely RIS,
ZOL, and IBAN, were evaluated for comparison with our results
of growth inhibition in N-BPs-treated C. parvum-infected MDCK
cells. As summarized in Table 2, the enzyme CpNPPPS was
Figure 3. Comparative Biochemical Study of Human and Parasite Prenyl Synthases
(A) Reverse-phase TLC of the product distribution from the reaction of CpNPPPS with various substrates in the presence and absence of detergent.
(B) Rates of IPP incorporation into product by CpNPPPS, human GGPPS (hGGPPS), and human FPPS (hFPPS) with different substrates.1300 Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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binding characteristics, with Ki and IC50 values in the same range
as the enzyme concentration (e.g. IC50,RIS is 45.7 nM with the
nominal enzyme assay concentration of 92 nM). The N-BPs
also showed the time-dependent characteristics of slow binding.
The initial inhibition of the enzyme by ZOL gives an IC50 value of
2.0 ± 0.2 mM and a Ki
app value of 2.2 ± 0.2 mM (see Figure S2 and
Table 2 for other N-BPs). Upon preincubation of the enzyme and
ZOL for 10 min, the IC50 decreased by approximately 70-fold.
Lineweaver-Burke analysis of the inhibition of the enzyme by
ZOL at different concentrations of one substrate while holding
the second substrate constant shows that the N-BP is compet-
itive for the allylic substrate (in this case FPP) and mixed
(noncompetitive) for IPP (Figure S3). This effect was not taken
into account in our calculation of the Ki
app value. With correction
made for substrate competition, we obtained Ki values of 0.38 ±
0.12 nM, 0.05 ± 0.04 nM, and 1.60 ± 0.26 nM for RIS, ZOL, and
IBAN, respectively. Clearly, all three drug compounds are highly
potent inhibitors of the CpNPPPS enzyme, supporting the
hypothesis that this is the mechanism of their anticryptosporidial
effectiveness as seen in the MDCK cultures.
Crystallography: CpNPPPS in Structural Complexes
with Clinically Relevant N-BPs
The structures of CpNPPPS-RIS (Protein Data Bank [PDB] ID:
2O1O), shown in Figure 4A, and CpNPPPS-ZOL (PDB ID:
2Q58) were determined to 2.42 A˚ (R = 18.6%, Rfree = 21.3%)
and 2.37 A˚ (R = 20.2%, Rfree = 24.1%), respectively (Table 3).
Nearly identical with rmds for Ca of < 0.5 A˚, these structures
reveal the enzyme to be a homodimer of subunits each made
up of a helices joined by loops—a typical trans-prenyl synthase
fold previously described for FPPS (Hosfield et al., 2004; Kava-
nagh et al., 2006b; Rondeau et al., 2006; Tarshis et al., 1994),
GGPPS (Guo et al., 2007; Kavanagh et al., 2006a), and OPPS
(Guo et al., 2005, 2004a). To be specific, the CpNPPPS-ZOL
structure deviates by 1.56 A˚ and 2.67 A˚, respectively, from the
human FPPS-ZOL/IPP structure (PDB ID: 2F8Z) and apo Ther-
motoga maritima OPPS (PDB ID: 2AZL). The two highly
conserved aspartate-rich allylic binding sites, namely FARM (first
Asp-rich motif) and SARM (second Asp-rich motif), are located
across an elongated central cavity enveloped by the helical
core in each subunit, also as seen in other prenyl synthases
(Chang et al., 2006; Kavanagh et al., 2006a, 2006b; Rondeau
et al., 2006; Tarshis et al., 1994). The FARM sequence in
CpNPPPS, specifically DDIMD, conforms to the DDXXD motif
(X being any residue), whereas the first aspartate in the SARM
is in fact an asparagine in this enzyme (NDVSD). Three Mg2+
ions are coordinated in an octahedral fashion through the Asp
of the FARM, the Asp and Asn of the SARM, and the bisphosph-
onate oxygens of RIS and ZOL. Despite its inclusion in the crys-
tallization condition, IPP was not found in either structure. Again,
as in other prenyl synthases, the drug molecule (RIS in 2O1O,
ZOL in 2Q58) is bound in CpNPPPS between helices a4, a8,
and a9 (see CpNPPPS-ZOL in Figure 4B and CpNPPPS-RIS in
Figure 4C). Key residues on each protein molecule interacting
with it include the carbonyl of Lys226 and the Oc of Thr227
(residue numbering based on sequence in CryptoDB gene
record cgd4_2550) in a manner found in Saccharomyces cerevi-
siaeGGPPS (for ZOL andminodronate) (Hosfield et al., 2004; Ka-
vanagh et al., 2006b; Rondeau et al., 2006; Guo et al., 2007).
Variations among prenyl synthases in the chain length deter-
mination (CLD) region hold the key to their substrate preference.
In enzymes that produce only FPPS, the chain-elongation cavity
is delimited by two bulky residues (FF) four or five amino acids
upstream from the FARM (Ohnuma et al., 1996a, 1996b; Tarshis
et al., 1996). In GGPPS, which has no bulky residues upstream of
the FARM, the triad of Leu67, Tyr107, and His139 is implicated in
the CLD (Chang et al., 2006; Guo et al., 2007; Kloer et al., 2006).
In OPPS from T. maritima, Phe132 has been shown to seal the
larger chain-elongation cavity (Guo et al., 2004b) necessary for
the C40 product. The new CpNPPPS enzyme lacks both the
phenylalanine tandem in FPPS and the GGPPS triad. In their pla-
ces are a less bulky (126LI127) pair and a smaller andmore flexible
triad of Ile123-Lys163-Val197. This relatively unencumbered
cavity can accommodate a large array of substrates, products,
and inhibitors, as visualized in Figure 5.
Despite its significantly larger active site, our crystallographic
structures reveal that the typical binding of small N-BPs in the
allylic binding site of prenyl synthases is preserved in CpNPPPS.
This is not the only mechanism of inhibition of prenyl synthases,
however, as shown in the inhibitor binding sites described for
S. cerevisiae GGPPS and the inhibitory binding of GGPP in
human GGPPS. Figure 5 shows some of the alternative possibil-
ities for inhibitor binding in CpNPPPS based on previous work
including: (1) the bisphosphonate moiety bound in the allylic
binding site and extended into the hydrophobic pocket typically
occupied by the growing isoprenyl chain (Figures 5A and 5C); (2)
the bisphosphonate moiety bound in the allylic binding site
where the remainder of the inhibitor is large and extends into
the novel GGPP inhibitor site identified in human GGPPS
(Figure 5F); (3) the bisphosphonate moiety bound in the homoal-
lylic IPP binding site and the inhibitor side chain extending into
the novel GGPP inhibitor site (Figure 5D); and (4) the diphosphate
bound in the IPP site and the isoprenyl chain extending into the
typical hydrophobic pocket occupied by the growing isoprenyl
chain (Figure 5E).
Unique Isoprenoid Pathway in Cryptosporidium Offers
Mechanism of Anticryptosporidial Action
Although humans have two distinct monofunctional enzymes
to respectively produce FPP and GGPP, this is not the case in
all organisms. For example, there are two reported archaeal
enzymes that yield both FPP andGGPP in a temperature-depen-
dent manner (Chen and Poulter, 1993; Fujiwara et al., 2004; Ta-
chibana et al., 2000). In Plasmodium parasites, there is only one
enzyme homologous by sequence to both human FPPS and
GPPS; it produces strictly GGPP in biochemical assays (data
not shown). Toxoplasma gondii FPPS produces a detectable
but unquantified amount of GGPP in addition to the dominant
Table 2. Enzyme Inhibition by N-BPs Found to Be Most Potent
Anticryptoporidial Compounds
IC50 (nM) Ki
app (nM) Ki (nM)
RIS 45.7 ± 2.6 4.6 ± 1.4 0.38 ± 0.12
ZOL 30.1 ± 1.1 0.60 ± 0.46 0.050 ± 0.038
IBAN 52.7 ± 7.6 19.4 ± 3.1 1.60 ± 0.26Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved 1301
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and at long reaction times (Ling et al., 2007). Both Plasmodium
and Toxoplasma employ the MEP pathway to manufacture IPP
and DMAPP as substrates for these enzymes. In contrast,
genomic analysis indicates the presence of neither the mevalo-
nate nor the MEP pathway in Cryptosporidium. However, there
is genomic evidence of enzymes involved in production of
long-chain pyrophosphates, including a putative long-chain fatty
acyl diphosphate synthase (CryptoDB gene ID cgd7_3730) and
a putative long-chain cis-prenyl synthase, undecaprenyl pyro-
phosphate synthase (cgd4_1510). Further downstream, farnesyl
tranferase (FTase) (cgd6_2510) has been implicated in presqua-
lene diphosphate synthesis and might be capable of catalyzing
the production of squalene from FPP and NADPH, a-subunit of
Rab geranylgeranyl transferase (GGTase, cgd7_5300), 2
b-subunit of Rab GGTaseb (cgd6_1750), Rab GGTaseb1
(cgd3_2350), GGTaseb (cgd1_1980), and UbiA prenyltransfer-
ase (cgd3_2460). Clearly, the parasite has the machinery to
utilize isoprenoids for myriad functions, but it has not yet
divulged its means to produce the requisite building blocks.
Although there might be other novel enzymes that perform this
function, the enzymatic versatility of CpNPPPS in vitro supports
the possibility of a salvage pathway, possibly enabling the para-
site to use whatever short- to medium-chain isoprenoids avail-
able from the host to manufacture longer products. In either
case, the Cryptosporidium isoprenoid pathway is entirely
different from what has been previously observed in all other
organisms.
Figure 4. CpNPPPS Structures
(A) Overall view of CpNPPPS dimer with RIS bound. Helices are numbered in the blue subunit and risedronate is labeled in the white subunit.
(B) Active site from structure of CpNPPPS with ZOL bound (2Q58). The three aspartate residues of the FARMmotif are shown (Asp131, Asp132, Asp135), as are
Asn270, Asp 271, and Asp274 from the SARM. Also shown are the other conserved residues that interact with ZOL - 226KT227, and the CLD dyad of 126LI127.
Residue numbering is based on sequence from the CryptoDB gene record cgd4_2550. (C) Electron density in risedronate-binding area with key residues in
FARM and SARM showing. Water molecules are in red and magnesium ions are in green.1302 Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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Currently, drug treatment for cryptosporidiosis revolves
around threedifferentstrategies thatarealsoused incombina-
tion: nonspecific antimicrobial drugs, immunotherapy (for the
immunocompromised), and symptomatic treatment with anti-
diarrheals, with none proven to be adequate (Mead, 2002).
Without any validated drug targets and candidates on the
horizon, an effective therapeutic solution appears a long way
off. The use of bisphosphonates might be a study in opportu-
nistic therapy for at least three main reasons. First, because
a number of compounds in this family are drugs in clinical
use with well-known pharmacokinetics, there is potential to
accelerate the preclinical investigations necessary before
testing these compounds in cryptosporidiosis patients.
Second, we identified three potent anticryptosporidials out of
seven N-BPs tested. This provides the impetus to study other
bisphosphonates to identify candidateswith an optimal profile
in potency and pharmacokinetics, without further chemical
development. Finally, whereas bisphosphonates’ poor
bioavailabilitymightmake themunsuitable formany infectious
diseases, they could be ideal candidates for cryptosporidiosis
treatment because the parasites congregate in the epithelial
cells of the gastrointestinal lumen (Lin, 1996) and therefore do
not require drugs to be transported through the blood system.
EXPERIMENTAL PROCEDURES
Reagents
All seven compounds used in this study—risedronate, zoledronate, alendro-
nate, pamidronate, NE10790 and NE58051—were provided by Procter &
Gamble Pharmaceuticals (Cincinnati, OH).
C. parvum Isolate for In Vitro Cultivation Studies
C. parvum oocysts (IOWA isolate) were generated in newborn Holstein bull
calves and stored at 4C in 2.5% (w/v) aqueous potassium dichromate (Arro-
wood and Sterling, 1987). Oocysts were purified from calf stool by sieving
through stainless steel sieves, followed by discontinuous sucrose gradient
and cesium chloride shelf gradient methods as previously described (Arro-
wood and Donaldson, 1996).
C. parvum In Vitro Cultivation Assay
Purified oocysts were diluted in UltraCULTURE synthetic culture medium
(Lonza Group Ltd., Switzerland) and inoculated onto confluent MDCK cells
in 2-well coverslip culture chambers (Nunc, Inc., Naperville, IL) and incubated
at 37C in a 5% CO2 incubator. Oocyst inocula typically contained 500–2000
oocysts/mm2 (1 3 105/chamber). After 3 hr (to allow excystation and sporo-
zoite invasion), the medium was removed, the monolayer was washed gently
with PBS (to remove unattached parasites), fresh growth medium was re-
placed (with or without test compounds), and the culture chambers were incu-
bated for a total of 48 hr (Arrowood et al., 1994). In each experiment, two repli-
cates were prepared for each concentration of the test compounds.
Table 3. Data Processing and Refinement Statistics
Protein Data
Bank Code 2Q58 2O1O
Crystal
Space group P31 P31
Unit cell a = b = 104.8A˚
c = 78.5A˚
a = b = 90, g = 120
a = b = 101.8A˚
c = 75.3A˚
a = b = 90, g = 120
Solvent content (%) 53 53
Matthews
coefficient (A˚ 3/Da)
2.6 2.6
No. of molecules
in asymmetric unit
2 2
Data collection
Wavelength (A˚) 1.5418 1.5418
Resolution (A˚) 50.0-2.2 50.0-2.42
Unique reflections 44405 32655
Redundancy 5.6 5.0
Completeness (%) 99.8 100
I/(I) 34.1 29.7
Rmerge (%) 3.8 4.6
Refinement
Resolution (A˚) 50.0-2.37 50.0-2.42
Completeness (%) 94.9 94.9
Unique reflections 33571 31541
Rall (%) 20.2 18.6
Rfree (%) 24.1 21.3
Number of protein
atoms
5313 5310
Number of water
molecules
48 28
B factor
from Wilson plot (A˚2)
66 53
Average B factor (A˚2) 60 57
Ramachandran plota
Most favored
regions (%)
82.7 86.7
Additional allowed
regions (%)
15.7 12.5
Generously allowed
regions (%)
1.0 0.5
Disallowed regions (%) 0.6 0.3
The crystal structure of human FDPS (PDB code: 1YV5), with all residues
converted to alanine, was used as a search model. The twinning did not
affect structure solution; and the fittedmolecular replacement model was
extended automatically with RESOLVE (Terwilliger, 2002) and rebuilt
manually with COOT (Emsley and Cowtan, 2004). The twinning matrix
(1 0 0 1 1 0 0 0 1) and twin fraction (0.39) were determined by The
Merohedral Crystal Twinning Server (http://nihserver.mbi.ucla.edu/
Twinning/; Yeates, 1997); and detwinned data were generated. For
map calculation, all data from the 50.0-2.2A˚ range were included, but
because of very weak data in the highest-resolution shell, the high-reso-
lution limit for refinement was set to 2.37A˚. Initial refinement against the
detwinned data was performed with REFMAC (Murshudov et al., 1997).
Refinement with REFMAC converged with R and Rfree equal to 27%
and 34%, respectively. At this point the original data were used again
and further refinement was carried out with SHELXL. The twinning frac-
tion was refined to 0.45. The final refined model and the structure factors
were deposited to the PDB under the accession code 2Q58 and were
used as a starting model for molecular replacement of the complex
with RIS. For the second crystal the initial twinning fraction, as deter-
mined by the Merohedral Crystal Twinning Server, was equal to 0.44
and increased to 0.49 when SHELXL was used for refinement. The final
model of CpNPPPS in complex with RIS, and its structure factors, was
deposited to the PDB under the accession code 2O1O.
aRamachandran plots were generated with PROCHECK.Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved 1303
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Cultures were fixed with Bouin’s solution, decolorized with 70% ethanol,
blocked with PBS supplemented with 0.1% bovine serum albumin (PBS/
BSA, 30 min at room temperature [RT]), and labeled with a Cryptosporidium-
specific monoclonal antibody labeled with fluorescein isothiocyanate (C3C3-
FITC) or with neat C3C3 hybridoma supernatant (60 min at RT). Chambers
incubated with unlabeled antibody were subsequently labeled (60 min at RT)
with fluorescein-conjugated goat anti-mouse immunoglobulin (Zymed Labora-
tories Inc., San Francisco, CA). Labeled cell cultures were washed with PBS/
BSA, overlayed with two drops of a glycerol-based mounting medium (with
fluorescence anti-quenching agent), coverslipped, and stored at 4C until
examined (Arrowood, 2002).
Culture chambers were examined using epifluorescence at 100Xmagnifica-
tion on a Zeiss Axiovert 200microscope (Carl Zeiss Microimaging, Inc., Thorn-
wood, NY). Seventy-two adjacent video frames (13883 1040 pixels) were digi-
tized from each culture chamber (treatment replicate) with a Zeiss AxioCam
HRm camera utilizing Zeiss AxioVision software. Life cycle stages were iden-
tified by reactivity with monoclonal antibody and by morphology (size and
shape). Developing meronts and gamonts (3–5 mm) were enumerated for
each treatment chamber replicate with assistance from freeware image anal-
ysis software (ImageJ, NIH, Bethesda, MD) as number/mm2 (Arrowood, 2002).
Parasite counts in treated chambers were comparedwith control chambers,
inhibition was calculated, and IC50 values were determined by median effect
analysis using CalcuSyn software (Biosoft, Cambridge, UK) (Chou, 2006).
Toxicity Assay
Bisphosphonate compounds were evaluated for toxicity using a tetrazolium
salt-based assay (CellTiter 96, Promega Corp., Madison, WI) in MDCK and
HCT-8 cells under conditions equivalent to those used for parasite culture.
Expression and Crystallography
An N-terminal truncation of cgd4_2550 (GenBank Accession: XP_625843)
from E38-L384 with an N-terminal His6-tag and TEV cleavage site
(MGSSHHHHHHSSGRENLYFQ*G) was cloned, expressed using the Lex
bioreactor system (Harbinger Biotechnology and Engineering Corp., Mark-
ham, Ontario, Canada), and purified as previously described (Vedadi et al.,
2007). Purified CpNPPPS was crystallized using the hanging drop vapor diffu-
sionmethod in a VDXmplate with 350 ml mother liquor at 18C. Protein solution
(1.5 ml of 10mMRIS or ZOL, 10mM IPP, and 10mMMgCl2) wasmixedwith the
reservoir solution (1.5 ml of 1.6 M (NH4)2SO4, 10 mM MgCl2, and 100 mM
HEPES, pH 7.5). Crystals appeared after 4–5 weeks. Diffraction data were
collected using a Rigaku FR-E Superbright generator equipped with a Rigaku
HTC image plate detector.
Enzymatic Assays
CpNPPPSwas assayed using themethod of Reed and Rilling with somemodi-
fications (Reed and Rilling, 1975). For the kinetic analysis, 400 ng (9.2 pmol)
purified CpNPPPS was assayed in 100 ml buffer (50 mM Tris [pH 7.7], 2 mM
MgCl2, 1 mM TCEP, and 5 mg/ml BSA). The concentrations of GPP and IPP
(14C-IPP, 400 KBq/mmol) were typically 0.05 to 20 mM. The remainder of the
assay was completed as described elsewhere (Kavanagh et al., 2006a). For
inhibition experiments, 10 ml 10x N-BP was added to each assay; and to allow
for any slow binding inhibition the enzyme was preincubated with the inhibitor
in a total volume of 80 ml. After 10 min, 20 ml of a substrate mixture containing
GPP and IPP (14C-IPP, 400 KBq/mmol) was added to start the reaction (giving
100 ml total volume and 10 mM substrate). Assays were carried out at 37C and
subsequently terminated, extracted, and analyzed as described previously
(Kavanagh et al., 2006a). Preincubation of enzyme and inhibitor experiments
showed tight binding characteristics, so data were evaluated as detailed
earlier (Kavanagh et al., 2006b). Analysis of the reaction products was
completed using reverse-phase TLC (Fujii et al., 1982). Briefly, the 14C-labeled
enzyme products were dephosphorylated and separated on a C18 reverse-
phase TLC plate (Analtech) using 3:1 acetone:water. The plate was then dried
and imaged using a Storm 860 phosphor imager (GE Healthcare). Vision-
WorksLS software was used for the calculation of the relative yields for the iso-
prenoid products, and results were corrected for the amount of radioactivity
incorporated into each product.
Crystallographic Data Processing, Structure Solution,
and Refinement
Datasets were processed with HKL-2000 (Otwinowski and Minor, 1997). The
protein crystallized in space group P31 in both crystals; and both crystals could
be classified as partial merohedral twins. The structure of CpNPPPS-ZOL was
solved by molecular replacement using MOLREP (Vagin and Teplyakov, 1997)
as implemented in CCP4 (CCP4, 1994). The twinning did not affect structure
solution; and the fitted molecular replacement model was extended automati-
cally with RESOLVE (Terwilliger, 2002) and rebuilt manually with COOT (Emsley
andCowtan, 2004). The twinningmatrix (h, -h-k, -l) and twin fraction (0.39) were
determined by The Merohedral Crystal Twinning Server (http://nihserver.mbi.
ucla.edu/Twinning/; Yeates, 1997). The final refined model and the structure
factors were deposited to the PDB under the accession code 2Q58 and were
used as a starting model for molecular replacement of the complex with RIS.
Figure 5. Predicted Binding of Substrates,
Substrate Analogs, Products, and Inhibitors
to CpNPPPS
Each image is created usingWinCoot SSM Super-
pose by superimposing the respective structure
and its associated ligand over CpNPPPS and dis-
playing the resulting ligand orientated within the
CpNPPPS-RIS structure. Visual inspection re-
vealed no obvious interference of the ligand with
the CpNPPPS structure. The Mg2+ ions from the
CpNPPPS-RIS structure are shown in pink; the
oxygens of the phosphate moieties are shown in
red.
(A) RIS (black), PDB ID: 2O1O.
(B) IPP (dark green), FsPP (light green), PDB ID:
2E8T.
(C) BP629 in allylic site (light blue), PDB ID: 2E93.
(D) BP629 in IPP site (dark blue), PDB ID: 2E8T.
(E) GGPP in IPP site and across to FPP site (bright
pink), PDB ID: 2E8V.
(F) GGPP in ‘‘inhibitor’’ site (orange), PDB ID: 2FVI.1304 Chemistry & Biology 15, 1296–1306, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
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Targeting a Uniquely Nonspecific Prenyl SynthaseThe final model of CpNPPPS-RIS (twin fraction 0.45) and its structure factors
were deposited to the PDB with accession code 2O1O. Both structures were
validated using PROCHECK (Laskowski et al., 1993), andMOLPROBITY (Lovell
et al., 2003). Data collection and refinement statistics for both structures are
summarized in Table 3.
SUPPLEMENTAL DATA
Supplemental Data include three tables and three figures and are
available with this article online at http://www.cell.com/chemistry-biology/
supplemental/S1074-5521(08)00448-1.
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